Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug to treat erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are main desired properties. Dicot's main strategy is to develop LIB-01 in-house up to and including clinical phase 2a study, and then in partnership with major pharmaceutical companies to finance and further develop LIB-01 into a registered drug for the world market.

Quotes for Dicot Pharma AB

Right Now

+/-
%
Latest
High
Low
Volume
Turnover ()
Time (Latest trade)

Board

CEO

  • Elin Trampe

Chairperson of the Board

  • Eva Sjökvist

Board

  • Fredrik Buch
  • Jan-Eric Österlund
  • Michael Zell
  • Mikael von Euler
  • Per-Göran Gillberg
  • Articles of association

    • News

    Show More

    Analysis

    Videos

    Pressträff Direkt

    Dicot - fas 1-resultat 2024

    Largest Owners

    Name Capital % Votes % Date
    Avanza Pension 8,96 8,96 2025-09-26
    Bertil Lindkvist 6,87 6,87 2025-09-30
    Tore Robertsson 2,97 2,97 2025-09-26
    Nordnet Pensionsförsäkring 2,80 2,80 2025-09-26
    Torsten Söderberg med familj 1,80 1,80 2025-09-26
    Klas Göran Strömberg 1,04 1,04 2025-09-26
    Michael Zell 0,92 0,92 2025-09-26
    Christian Lentz 0,84 0,84 2025-09-26
    Swedbank Försäkring 0,77 0,77 2025-09-26
    Kent Öhlin 0,72 0,72 2025-09-26

    Annual reports, prospectus etc.